



The Challenging Role of Flavonoids as a Potential Phytochemical to Treat Anxiety

Arbaz Khan, Avijit Mazumder* and Jatin Saini

Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida - 201306, Uttar Pradesh, India; avijitmazum@yahoo.com

Abstract

Numerous mental diseases can be caused by anxiety or anxiety-like effects, but phobia is a prevalent overcoming symptom that frequently causes stress. At present, two primary anxiety-treatment approaches are being considered: Psychotherapy and pharmacotherapy. So many traditional synthetic anxiolytic drugs with such a variety of side effects are used in the pharmacological clinical approach. As a result, scientists are searching for studies that will help them find suitable safe medications from plant sources. Large experimental studies have assured that dietary phytoconstituents such as terpenoids, alkaloids, phenolic compounds, flavonoids, lignan, saponins, and cinnamates, and plant infusion comprising a combination of the various substance, have stronger action in a variety of the anxiety models in animals. The mechanisms of action of anxiolytics involve relationships with the GABA A receptor on both non-BZD sites and in Benzodiazepine (BZD).

Keywords: Anxiety, Depression, Flavonoids, Medicinal Plants, Phytoconstituents, Traditional Medicine

1. Introduction

Anxiety condition is the most familiar type of manic disorder in the United States and several different countries and its parts. Anxiety disorders are classified by the Diagnostic and Statistical Manual of mental disorder (DSM) American Psychiatric Association, 2001, anxiety disorder includes panic attack, apprehension, post-traumatic maniac condition, anxiety condition, expanded, stress about social conditions, Compulsive Behavior Disorder (OCD) expressed by invasive, and avoid potential¹.

Anxiety disorders are linked to serious disability rates of chronic conditions, and elevated numbers of comorbid conditions for identical intersect for a wide range of brain disorders (mood problems). We begin this review article with a short description of neurofunction and the neurological parameters of anxiety and fear using the most recent transcriptional models¹. Then, we look at some of the newest promising ways in neurochemistry anxiety investigation, with a special focus on transcriptional findings related to the creation of new therapies. Anxiety is a harmonic situation of emotional stimuli that include

feelings of fear or worry. Patients with worry, as opposed to patients with fear, frequently understand danger sources only vaguely. Anxiety is the most common behavioral problem, according to studies, and studying factors that affect students' anxiety reveals that physiological features, items relating to growth phases, and social, relatives, and factors all have a major impact on anxiety. Anxiety disorder affects approximately 500 million people worldwide². Anxiety manifests itself in a variety of mental and physical symptoms, such as increased heart rate, stomach cramps, perspiration, bronchitis, motion sickness, tired, urination, a condition of apprehension and anxiety, failure to meet a role, doubt about the future, the anticipation of a sad event, inability to concentrate, poor sleep³.

2. Neuroanatomy of Fear and Anxiety

Amygdala is a primary brain part responsible for the passing of frightening material, as it relays the immediate threat response by incorporating knowledge from sensory properties, relevance, and previous knowledge using

*Author for correspondence

subcortical and cortical inputs⁴. Sensory input attains the central nervous system via the frontal thalamus in the organism's fear response, imploring the amygdala to start physiological and neurogenic reactions through forecasts by the cortex and brain tissue nuclei portion. Fear, a comparatively short, sensory reaction, and anxiousness, a more prolonged reaction stimulated by situations of unpredictable hazard, have distinct amygdala pathways in rats⁵. The old pathway involves the amygdala's basolateral, central, and medial nuclei, whereas the latter includes forecasts from the dorsal motor amygdala to the stria terminalis bed nucleus. According to a meta-analysis of neuroscience, scared stimuli especially activate the stress response in healthy human participants, which is consistent with animal literature⁶. According to human neurocircuitry models, amygdala action is enhanced by top oversight of the medial prefrontal portion such as the orbitofrontal part, and through the midbrain, permits relevant pieces of information like a sense, accurate memory characterizations, and consciousness to promote danger-restoring. amygdala and frontal cortex have a mutual relation and are also involved in a near-extinction mode⁷. A distinctive pattern of enhanced amygdala reactions to threat signals has been recorded in a variety of anxiety disorders and can be witnessed in the very initial stages of analysis, such as when a masked trigger design precludes awareness of stimulation⁸.

3. Currently Marketed Drugs for the Management of Anxiety Disorders

Therapies and pharmacologic options Historically, Tricyclic Antidepressants (TCAs) were used. There are various treatment options for anxiety disorders, such as Cognitive behavioral treatment, that have uses broadly utilized for the rehabilitation of patients and have shown comparable capabilities to SSRIs for severe anxiety and




Figure 1. Neuroanatomy of fear and anxiety.

Generalized Anxiety Disorder (GAD). TCAs, on the other hand, have small tolerable adverse effect benefits and safety problems (including objectionable anticholinesterase and cholinergic effects), as do Mao inhibitors (adverse results involve sleeplessness, hypnotics, low bp, sexual problems, episodes of mania, weight acquire, hypertensive episode, and tonic-clonic jerking)⁹. Serotonin reuptake inhibitors (e.g., venlafaxine, phenelzine, Zoloft) are first-line therapeutical agents for all mental illnesses, with proof from multiple, randomized, non - randomized experiments that lead to their own activity and safety. Serotonin-norepinephrine reuptake inhibitors (for example, duloxetine) also becoming primary treatments for stress and depression, most notably generalized anxiety. SNRIs and SSRIs inhibit serotonin and noradrenaline reuptake after discharge from the brain, properly, increasing their availability at the synaptic cleft, neurotransmission efficacy, and resultant effect in another neurotransmission⁹. paroxetine's slower therapeutic onset (2 to four weeks) relates to subtle improvements in brain function and structure. Animal studies have shown that SSRIs' behavioral effects are aided by the development of new cells within the hippocampus. while changes in mobility may be the possible mode that these drugs help counter hyper effects to pressure in depression and anxiety¹⁰.

3.1 Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors (SSRIs and SNRIs)

The first-line use of paroxetine (SSRIs) and duloxetine (SNRIs) is advised due to their superior benefit/risk balance. Patients should be made aware that these antidepressants start working their anxiolytic effects 1 to 3 weeks after taking them (up to 6 weeks). The negative effects could be more pronounced for the first two weeks. There may be acute muscle twitching or a rise in negative symptoms, which could make it harder for patients to adhere to their treatment regimens. These negative effects could be lessened by decreasing the antidepressant's initiating dosage. According to a review of research done on depressed patients, SNRIs may not be as well tolerated as SSRIs¹¹.

Yet, medical condition suggests that desirability varies and that a specific patient could lower side effects when switching between an SSRI and an SNRI.


Table 1. List of medications currently used in the management of anxiety along with their MOA and AE

Class of medication	Examples	MOA	Adverse Effects
SSRIs	Citalopram Escitalopram fluvoxamine Paroxetine Sertraline Duloxetine Fluoxetine	5HT reuptake is selectively inhibited.	Nervousness, nausea, impatience, diarrhoea, bowel problems, tiredness, vomiting, blurred vision.
SNRIs	Venlafaxine Duloxetine	By blocking neuronal reuptake of 5-HT and NE, it improves monoaminergic function.	Nervousness, nausea, impatience, headache, tiredness, tremors, libido problems, stomach pain, appetite change, nephritis.
tricyclic antidepressant	Clomipramine	Blocking the NET and SERT inhibits 5-HT and NE reuptake.	Side effects include pharmacological effects, somnolence, blurry vision, CVS problems, weight loss, glare in eyes, loss of libido, vomiting.
Calcium modulator	Pregabalin	Pregabalin, a novel mode of action (MOA) compound, has shown efficacy as an adjuvant therapy epilepsy medication in several neuropathic pain models. Pregabalin has the same efficacy as benzodiazepines and venlafaxine in several studies for generalized anxiety disorder (GAD).	Dizziness, somnolence, sore throat, edema, loss of vision, weight gain, bowel problems, euphoria, balance disorder, reduced appetite, difficulty concentrating/attention, or other side effects.
5-HT1A agonist	Buspirone	5-HT1A receptor selective agonist.	Dizziness, vomiting, sleeping problems, nervousness, chest pain, and other symptoms may occur.
α_2 -antagonist	Mirtazapine	Presynaptic α_2 -receptor improves monoaminergic function by disinhibiting 5-HT and NE release.	Agitation, mental confusion, fever, migraine, loss of coordination.

Just because a few SSRIs and SNRIs are cytochrome P450 enzyme inhibitors, they may communicate with other psychostimulant medications and treatments for medical illness¹¹. Withdrawal symptoms can occur after discontinuing SSRI treatment. However, such is much less severe and common than the symptoms of withdrawal seen after discontinuing benzodiazepine therapies. These side effects could be highly common in relation to citalopram other than with mirtazapine.¹²

3.2 Calcium Modulator

Pregabalin is just a calcium mediator medication that works by binding to the subunits of the calcium-gated channel. The calcium modulator has sedative effects. Sleep problems, that are prevalent in anxiety disorder groups, may improve sooner by pregabalin than if it is

**Figure 2.** Citalopram.

related to SSRIs. Pregabalin has a quicker onset of efficacy than antidepressant medications. Pregabalin does not undergo renal biotransformation and therefore does not relate to cytochrome P450 enzyme stimulators. However,

there have been reports of pregabalin abuse in people that suffer from drug addiction and detachment etiologies after abrupt discontinuation¹³.




Figure 3. Pregabalin.

3.3 Tricyclic Antidepressants

Conventional pharmacological interventions (TCAs) clomipramine and imipramine are just as efficient as 2nd antidepressant medications in anxiety disorder treatment. TCAs have a higher rate of adverse reactions than SSRIs or SNRIs. As a result, such treatments must be attempted before TCAs are used. The amount should be steadily increased until it reaches the levels utilized in depression treatment. TCAs should be utilized with caution in individuals who are recognized as suicidal because of their possibly fatal toxicity within a week of overdose¹⁴.




Figure 4. Imipramin.

3.4 Serotonin Receptor Agonist

Buspirone, a serotonin receptor 1A (5-HT_{1A}) agonist, is effective in the management of anxiety in some controlled studies. Not all the protocols, however, demonstrated dominance to control and/or comparability to marketed drugs¹⁴.

3.5 Benzodiazepines

Benzodiazepines sedative effects start shortly within a week of oral or parenteral administration. Benzodiazepines,




Figure 5. Buspiron.

except antidepressants, do not cause higher jitteriness and insomnia at first. In the U.S. benzodiazepines are used to treat 56% to 95% of patients who suffer from anxiety. Like, many studies have shown a high chance of benzodiazepine need. However, benzodiazepine usage is attached to central and peripheral system (CNS) anxiety, which can cause fatigue, drowsiness, enhanced reflexes, impaired vision abilities, and other unwanted effects. Memory functions, particularly in the elderly, may be impaired. Long-term benzodiazepine treatment (e.g., 4 to 8 months) may result in dependency in some patients, particularly in individuals naturally inclined to substance abuse¹⁵. Tolerance (characterized by an individual's steady thought to select the right dose) appears too uncommon. As a result, before beginning benzodiazepine treatment, the risks and advantages should be carefully considered. Benzodiazepines were not preferred as first-line treatments according to the current guidelines. The direction to use newer antidepressants depends on the well-known risks of benzodiazepines rather than direct comparative studies¹⁶.

3.6 Mao Inhibitor

Moclobemide is a monoamine oxidase inhibitor that is both selective and reversible. It is used to treat seasonal affective disorder. Because none of the studies have found the drug to be superior to a placebo, it is not suggested as a primary diagnosis¹⁶.

3.7 Antidepressant

The antidepressant medicine agomelatine, which behaves like a ligand for MT₁ melatonin neurons as well as an opponent for the serotonin 5-HT_{3C} target, is shown to be useful¹⁷. Even so, the drug is only approved to treat major depression, not GAD. Withdrawal signs and sexual problems are less likely with agomelatine even than with Selective serotonin reuptake or SNRI antidepressant medications. Hepatic enzyme elevations occur in approximately 14% of treated patients¹⁸.




Figure 6. Barbitol.




Figure 7. Moclobimide.

3.8 Antipsychotic

A few studies on Generalized Anxiety Disorder (GAD) have shown that the antipsychotic drug quetiapine is efficient. It is typically prescribed in doses ranging from 150 to 600 mg/day for therapies for schizophrenic psychoses. A smaller dose of (40 to 350 mg/day) is essential to treat anxiety. Nowadays, most countries did not approve of the drug for anxiety disorders, most likely because of side effects like metabolic syndrome. In general, patients who received lower doses experienced fewer classic side effects, like sedatives or weight gain. Only in treatment-refractory patients can drugs be used off-label. Efficacy begins sooner than with antidepressants¹⁹.

4. Phytotherapy

Several observational trials have shown that an oral administration of lavender oil can help in GAD and combined anxiety²⁰, still is unknown as to if the lavender




Figure 8. Agomelatine.




Figure 9. Quetiapine.

extract is good as standard medication. The relational experiments used small concentrations of the rivals, such as 20 mg fluoxetine in a day for day 50 and a single tablet of diazepam 1.5 mg in a day 69, which may cause resulted in the rival drugs being ineffective. Kava (*Piper methysticum*) studies yielded inconclusive outputs²¹, and the decoction was taken out from sale from certain places by its hepatic injury in different formulations. The non-API controlled studies of depressed groups, Valerian extract is ineffective²². John's wort was not also successful in generalized anxiety disorder. Different phototherapeutic was studied for groups of people with anxiety disorders. The proof for the examined products is insufficient because of the low standard of these studies. In herbal preparations, standardization may be a problem. It was discovered, for example, the material of the putatively efficient ingredients varied significantly between various plans of St. John's wort²³.

5. Flavonoids-Rich Plants with Anti-Anxiety Properties (Table 2)

5.1 *Aegle marmelos*

Aegle marmelos also referred to as bail (or bili or bhel), is a unique tree variety belonging to the Indian part and Southeast Asia. It is also known as Bengal quince, Japanese

tangerine juice, stone apple, or wood apple. It is found in the nations of India, Nepal, Sri Lanka, and Burma. Several studies on *Aegle marmelos* have shown that flavonoids are present in phytochemical analysis, which is liable for the anxiolytic impact via benzodiazepine receptors. As a result of the antianxiety and anti-depressants, the activities of *Aegle marmelos* are potentially due to flavanols. Other than flavonoid, numerous reports on *Aegle marmelos* have revealed the presence of phytochemicals such as tannins, quinones, marmesin, ascorbic, skimmianine, saponin, and eugenol, among others, which results in antianxiety effects. *Aegle marmelos* can be an effective and secure treatment meant for a variety of anxiety disorders. Ethanolic extracts are present in the fruit. These are prescribed to treat tiredness, anxiety, and depressed

mood. Glucocorticoids, coumarin, and alkaloids are found in the fruit²⁴.

5.2 *Rauwolfia serpentina*

Rauwolfia serpentina, also known as Indian snakeroot, devil pepper, as well as serpentine wood, is a milkweed flower in the Apocynaceae family. Its native range includes the Indian subcontinent and Asia (from Indonesia to India). The root of *Rauwolfia* is used to treat high BP and insanity in humans. also used to manage nervous system problems like stress and phobia. The use of serpentine to treat sleep patterns, brain illnesses, and rude behavior. It soothes anxiety condition and decreases stress and aggression behaviour. It has the potential to treat

Table 2. Flavonoid containing antianxiety plants with other biological activities

Sr No.	Plant	Part used	Therapeutic compounds	Screened activities
1	<i>Aegle marmelos</i>	Leaves and roots	Aegeline, Coumarin, Marmeline	Immunogenic, anti-diabetic, and anti-fertility
2	<i>Aloysia triphylla</i>	Root	Flavanone (Artemisinin, Hesperidin)	anti-malarial, Antidepressant
3	<i>Avena sativa</i>	Seed	Carotene, polyphenols, antioxidants	Eczema, skin rash,
4	<i>Bacopa monnieri</i>	Root, stem, leaf	Alkaloid, brahmine, serine, triterpenoid	Sedative, antiepileptic, memory enhancer
5	<i>Cimicifuga Racemosa</i>	Roots	Actaealactone, cimicifugic acid	Kidney disorder, rheumatism, snakebites
6	<i>Citrus aurantium</i>	Flowers	Flavanone glycosides and hydroxycinnamic acids are examples of phenolic compounds.	Antidepressants, anticonvulsants, antianxiety, and antioxidants.
7	<i>Echium amoneum</i>	Leaf and buds	Gama linolenic acid, palmitic acid stearic acid.	Antihyperlipidemic, cholesterol-lowering, antimicrobial, anti-diabetic, and antioxidant.
8	<i>Embilica Officinalis</i>	Leaf, flower	Catechol, gallic acid, quercetin.	Anti-inflammatory, anti-cancer, and anti-diabetic characteristics.
9	<i>Lavandula angustifolia</i>	Flowers	Hydroxycinnamic acids and flavone glycosides are examples of phenolic compounds.	Anxiolytic, antidepressant, anticonvulsant, and antioxidant.
10	<i>Melissa officinalis</i>	Bark and leaf	Rosmarinic acid, threeterpinene, flavon glycoside, Z citral.	CVS, Antirheumatic, Antiepileptic, Anxiolytics, Antidepressant.
11	<i>Piper methysticum</i>	Leaves	Chalcones, Kavalactones.	Respiratory problems, Anticonvulsant,
12	<i>Rauwolfia serpentina</i>	Roots	Ajmaline, reserpine, serpentine	Hypertension, anxiolytics, sedative
13	<i>Rosmarinus officinalis</i>	Leaves	Cineol, camphor, linalool	Spasm, antidepressant, rheumatic pain
14	<i>Valeriana officinalis</i>	Flowers	Valerenic acid, hydroxyvalerenic acid, acetoxyvalerenic acid.	sedative, antiepileptic, analgesic, purgative, antiseptic, and antihyperlipidemic properties.
15	<i>Viola odorata</i>	Leaves and flowers	Cycloviolacin O2, eugenol, phytol, octadecanoic acid.	Antidepressants, antihyperlipidemic agents, anticholesterol agents, antineoplastic agent.

symptoms, seizure disorders, schizophrenia, and mental illnesses^{24,25}.

5.3 *Rosmarinus officinalis*

Salvia rosmarinus, also defined as rosemary, is a Mediterranean herbaceous plant with a good smell, natural thread leaf, and pale, purplish, or dark flowers. It was previously known as *Rosmarinus officinalis*, which is now a synonym. It associates with the Lamiaceae family of sages and consists of different other therapeutic or culinary herbs. “Rosemary” is derived from the Latin term Ros Marinus Officinalis. Rosemary’s roots are fibrous. In folk medicine, *Rosmarinus officinalis* L. has most of the therapeutic benefits in healing or trying to manage a broad range of problems, including mania and stress. The content of *R. officinalis* had an anti-anxiety-like effect because it lowered, the immobility period swimming test in rodents when relate to the control. findings give that *R. Officinalis*’ antidepressant result is activated by communication and by the monoaminergic pathway and the plant must be studied later as a different treatment target in the management of anxiety²⁶. In recent years, rosemary diterpenes demonstrated *in vitro* and *in vivo* to restrict neuronal death caused by a variety of agents. The chemical constituents’ multifunctionality is discussed, ranging from overall antioxidant and anti-neuronal preservation to other exact methods such as neuroinflammation and amyloid beta formation²⁷.

5.4 *Avena sativa*

Avena sativa is primarily used to treat muscle spasms and mental conditions associated with debilitation. Heart problems, uneven seminal discharge issues, and convalescent mental problems are all general signs of *Avena sativa*. (Totho Shastho) Naturopathic *Avena sativa* seems to have a selective effect on the nerves of the gastrointestinal apparatus in male function neurasthenia. Because of its ability to selectively affect the entire nervous structure that provides the reproductive organs. This remedy can easily remove nervous muscle twitches in the heart, sleeplessness, nervous problem, central condition, and overall problem caused by overdoing masturbation²⁷.

5.5 *Bacopa monnieri*

Bacopa monnieri is a creeping herbaceous plant origin in the ponds of India, Australia, Germany, Africa, China, and South America. Water hyssop, thyme-leafed Graciela, the

rhizome of grace, and Indian pennywort are some of their common names. So many studies have shown that *Bacopa monnieri* leaf extract protects against neurodegeneration in animal models. Memory, anxiety, and brain health are all improved by the herbal remedy and extract. It’s also used to treat seizures, pharmacological material, cognitive function, and improve memory function. It aids in the treatment of depression and attention-short overreact disorder. In healthy older study participants, the whole plant standardized dry extract affects brain abilities and its safety and tolerability. The study adds to the fact that it has the main to safely improving brain activity in the elderly²⁸.

5.6 *Embllica officinalis*

Phyllanthus emblica, also defined as myrobalan, emblic myrobalan, Indian mulberry, Malacca plant, or amla, is a deciduous tree in the family of Phyllanthaceae. It is natal to South Asia. Memory problems, psychological tiredness, stress with emotional irritability and sleeplessness, anxiety with hostile responses, and attention deficit disorder can all benefit from *Embllica officinalis*. Amla can help with the following health issues: Memory problems, mental lack of energy, and vertigo are all symptoms of brain and nerve discomfort with a burning sensation, a pain with vibrating and throbbing pain, and vertigo. Stress with mental tiredness and agitation, depressed mood with forceful reactions, insomnia, and violent mental agitation are examples of psychological diseases²⁹.

5.7 *Valeriana officinalis*

Valeriana is the flowering plant genus belonging to the family of Caprifoliaceae, the members of which are usually referred to as valerians. It includes many species, including *Valeriana officinalis* and garden valerian. Valerian extract can induce sedation by increasing GABA levels in the brain. Sedative neurotransmitter like GABA is important, and in a high number of concentrations, leads to sedation. Based on the findings of the in-lab study, valerian could induce inhibitory neurotransmitters to also release from brain fibers and prevent GABA, forced to return in neurons. Furthermore, Valerian’s valerenic prevents the recurrence of an enzymatic activity that demolishes GABA and is yet another method that valerian could really boost GABA amounts and promote a good night’s sleep. Researchers discovered that valerian origin increases the quantity of a substance in the CNS referred to as GABA. GABA

regulates nerve cells and reduces anxiety. Alprazolam and diazepam, for example, have GABA concentration increases in the brain. The anti-anxiety properties of valerian root extract are due to the presence of valerenic acid and valerenol. Incredibly, an herbal supplement such as Valerian could exert the anxiolytic impact as prescribed medicines with the least adverse effects. It has calming and anti-anxiety properties²⁹.

5.8 *Aloysia triphylla*

Aloysia triphylla belonging to the family of the Verbenaceae would be a persistent, occupied herb native to America that is now grown throughout the Middle East. Traditional medicine has long used *Aloysia triphylla*. This herb is showing a mild sedative effect and aids in the management of anxiety³⁰. The flower has a stimulant effect on the brain and is known to relieve abdominal pain³¹. The herb has been discovered to have antioxidant properties³². Phytochemical studies of *Aloysia triphylla* aerial parts produced the discovery of various substances, artemether, and hesperidin³³. Artemis is said to have anti-inflammatory properties. Furthermore, artemisinin has been shown to relax smooth muscles³⁴. Hesperidin is a bioflavonoid glycoside that shows a variety of medicinal properties. And showing to resemble antipyretic and analgesic properties³⁵. different pathways, such as inhibition of secretion and reduction of eicosanoid synthesis have been proposed to explain such activity. Hesperidin is also discovered to have central nervous depressant effects³⁶.

5.9 *Citrus aurantium*

Citrus aurantium L is a fruit which is belonging to the family of Rutaceae, also termed as bitter orange (local names: laranjaazedada, laranjacavalo), is utilized in Brazil as remedies and in different states to reduce stress and depression and works as an antiepileptic, with major depression effects on the CNS. extract oils, particularly with citrus substance, are widely employed for treatments of mood and anxiety-like conditions³⁷, peeling out of extract oil is thought to generate mental calmness³⁸. Bitter orange seeds were made up of twenty-two phenolic compounds, such as hydroxybenzoic acids, ferulic acid, flavonoids, quercetin, simple alcohol, and coumarins³⁹. Human studies indicate that inhaling various types of oils is beneficial in decreasing psychological stress, anxiety, and cortisol levels in hypertensive patients⁴⁰. The sharp

impacts of natural extracts on centrally depressed people and anxiety have attracted the attention of researchers because they may be a viable replacement for synthetic substances that cause sedation, memory changes, and drug interactions⁴¹.

As an important Iranian folk remedy, Echium (*Echium amoenum*) from the Boraginaceae family is commonly employed as a natural remedy, tranquilizer, diaphoretic, and treatment for shortness of breath, sores, and pneumonia⁴². Antimicrobial, antioxidant, analgesic, anxiolytic, antidepressant, and immunomodulatory properties are thought to exist in this plant⁴³. *E. amoenum* decoction has also been shown might be effective in the prophylaxis of intense conditions. *E. amoenum* wet light blue leaf has recently been identified as an essential component of alcoholic components such as cyaniding, as well as delphinidin⁴⁴. The most popular anthocyanin, cyanidin 3-glucoside, found in the leaf of *E. amoenum*, reduces PGE1 synthesis and cox-1 expression by suppressing the excitation and hybridization of NF-B condition to the mitochondria⁴⁵. Min *et al.* also evaluated the neuroprotection action effect of cyanidin 2-glucoside. They hypothesized that the positive impact is due to a reduction in brain superoxide reaching the level by inhibiting apoptosis-inducing component discharge in the nucleus⁴⁶.

5.10 *Lavandula angustifolia*

Lavender is an established plant with a broad past in the traditional medicine system that is now used pharmacologically nowadays. The component extracted through the condensation process through the new flower extract of the *Lavandula* plant is commonly fit as a relaxant in therapy⁴⁷. In both animal and human studies, inhaling the droplets of oil and its primary components, terpenes has been proven to have calming effects⁴⁸. The different therapeutic actions of the oil have been reported, along with antiepileptic, antianxiety, anti-suppressive, and conflict impacts⁴⁹. Lavender, on the other hand, is used to treating restlessness, trouble sleeping, and worried ailments of the intestinal tract and stomach as just a tea infusion (i.e., soluble extracts). Lavender also includes aqueous phenolic constituents like cinnamic acid, and glycosides, which are related to the oxidant capacity of Lamiaceae⁵⁰.

5.11 *Melissa officinalis*

Melissa officinalis is a tropical plant which is belonging to the family of the Lamiaceae, also known as lemon balm, and is a herb native to the South American region and southwest part. In Iran country, lemon balm is known as “Badranjboyeh” and is found mainly in the regions of Iraq, Golestan, Azarbayjan, Lorestan, and Kermanshah⁵¹. The soaked or new petals and upper region of the herb are utilized as medication, Melissa has traditionally been utilized as a stimulant, demulcent, carminative, and medical application for wound healing, insomnia, memory boosting, depression, and alleviation of headaches. Lemon balm was also used in traditional Iranian medicine to manage restlessness or anxiety mainly in women and decreased enthusiasm-related activity and anxiety⁵². *Melissa officinalis* was prescribed by Ibn Sina a reputed Iranian researcher, for the mentioned purposes. essential oil's major components are 40% citronellal, 34% citral, and 3% geraniol. Furthermore, Melissa contains in low concentrations rosmarinic acid, phenol, three terpinene, flavanone, and glycoside acids. The claimed crude extract of lemon balm, which is commonly utilized in essential oils, is helpful for mild stress. *Melissa officinalis*, often referred to as lemon balm, is mainly taken for the pharmacological approach to make the mixture for its relaxing of nerve and antispasmodic action⁵³, but several phytopharmaceutical formulations contain this plant or its derivatives. Due to its flavor, this plant is often utilized in the culinary industry to flavor various items. The person facing neurological illness has recently been high number over the world, particularly in wealthy countries⁵⁴. Neurodegenerative disorders (Parkinson's, Alzheimer's) and mental diseases (depression or anxiety) are among the most common⁵⁵.

5.12 *Viola odorata*

Viola odorata is a small flowering plant that seems to be a group of *Viola* inbred to Africa and Austria that is spread to the United States or Australia. Wood violets⁵⁶, pleasant violet, English violet, regular violet, or garden violet are all names for it. This flower's pleasant scent has proven famous across the centuries, especially later Australian age, and is mainly used in the manufacturing of several clinical scents⁵⁶. In the past used to treat anxiety, and sleeplessness, and reduce BP. Violet is mostly used as a herbal medicine for a variety of respiratory illnesses. It can be highly effective in treating asthma, coughs, and sore throats.

Recent research has revealed the number of glycosides in Popular flowers, which shows efficacy in the case of angina and bodily problems. The Typical Violet flower syrup possesses antiseptic, anti-inflammatory, laxative, and cough suppressant effects. It can aid with a variety of respiratory diseases, as well as headaches, sleeplessness, dizziness, and tiredness⁵⁷. *Viola* includes an alkaloid, a flavonoid, terpenoids, methylsalicylate, and mucilage, and rich in vitamins and used as a diuretic agent, as well as other positive effects, but no research on cardiovascular disease efficacy has already been identified⁵⁸.

5.13 *Cimicifuga racemosa L*

Governing organizations approved the usage of *Racemosa L*. For a variety of indications, including depressed mood swings⁵⁹. Several research on *C. racemosa* (black cohosh) has demonstrated that it is mainly used in the management of anxiety problems⁶⁰. Triterpene is present in the oil of *C. racemosa*, as are aromatic compounds, tannin, resin, and fatty acids. a strong transmitter of SSRI 2-HT1A and the 3-HT7 target was recently discovered in the rhizomes of *C. racemosa*⁶¹. In the widespread benefits of *C. racemosa*, particularly at the time of the menstrual cycle, human investigations discovered no major anti-anxiety result in contrast to control. Smaller samples, the selection of cohosh formulation, and the drug employed in these investigations may have been limiting factors⁶².

5.14 *Piper methysticum*

P. methysticum G. Foster (kava) has been approved by herbal medicine regulatory organizations in the management of human therapy of moderate to severe points of phobia. It is just linked to stress, phobia, sleeplessness, and comorbid disease⁶³. Kava is an Ocean herb that has traditionally been used as an anxiolytic. Among some of the beneficial compounds identified in Kava are kavalactones like kavain, dihydrokavains, and yangonin. Recent research into the mode of action of isolated kavain has indicated activity on the 39/nuclear factor-kappa/cyclo-oxygenase 2 signaling pathway. Kava inhibits voltage-gated ion channels by binding to Na channels in their resting condition and prolonging their unstable⁶⁴. Kavain can suppress MAO-B and prevent noradrenaline uptake produced in the frontal lobe and of rats⁶⁵. Furthermore, showed that dihydrokavain and yangonin have COX-1 and COX-2 inhibitory activities. Lehmann and colleagues conducted clinical research in

1996 that established the benefit of Kava isolate vs. placebo in individuals suffering from anxiety⁶⁶ and discovered a substantial decrease in the unstable state of the brain in the Kava when relate to the control group. However, some publications in recent years have suggested that kava may cause hepatotoxicity⁶⁷.

6. Other Essential Flavonoids Act as anti-Anxietic Agents

6.1 Apigenin

A 4', 5, 7-trihydroxy flavone called apigenin is found in fruits and vegetables. Numerous medicinal actions, including antineoplastic, analgesics, and antioxidant effects, have been reported. The anxiolytic potential of apigenin published in several pre-clinical studies. Using a forced swim test on rodents, Nakazawa investigated the antianxiety role of apigenin and discovered that it improved resistance-like behavior in animals, which was demonstrated by the dopaminergic pathway⁶⁸. In a different study, apigenin was discovered to have an antidepressant role in mice tested with the help of an unpredictable chronic model of mice. According to the researcher's analysis, action may be caused by two increases in the expression of the PPAR (peroxisome proliferator-activated receptor), which inhibited the NLRP2 and ILL synthesis⁶⁹. Apigenin's antidepressant mechanism has also been confirmed by its role in upregulating hippocampal BDNF levels and inhibiting the mono-amino oxidase enzyme. Due to its potential to reduce inflammation⁷⁰.




Figure 10. Apigenin.

6.2 Baicalein

Trihydroxyflavone flavonoid baicalein has hydroxyl compounds at positions 5, 6, and 7 of the carbon atoms. The most active flavonoid found is baicalensis, according to research⁷¹. Baicalein is a potent compound that resembles many actions such as antioxidant and free radical scavenging action, according to numerous reports⁷¹. According to published research, this flavone

significantly shows calming effects and CNS depressant effects and crosses the blood-brain barrier⁷². Additional research has indicated that baicalein, which was purified from the ethanolic extraction of the root of *Scutellaria*, may suppress the brain, function in a decrease in prostaglandin E2 levels in the brain, as well as act as a potent antioxidant and prevent the development of depressive behavior in mice model. Prostaglandin E2 levels in the brain were found to be reduced in 6 of 48 rodent brains. This substance also serves as a potent antioxidant and aids in the control of chronic stress behavior in mice⁷³.




Figure 11. Baicalein.

6.3 Myricetin

Hexahydroxy flavone myricetin has hydroxyl groups substituted at positions 3, 3', 4', 5, 5', and 7 of the carbon atoms. Many substances like, vegetables, dry fruits, rum, and tea are all very plentiful. Its analgesic, antineoplastic, and anti-depressant effects have been verified⁷⁴. In a study, it was discovered that myricetin reduced depressive behavior in mice under stress, which was predicted by the FST. The anti-depressants potential of myricetin was boosted by the findings that this flavonol decreased plasma levels of corticosterone, improved reactive oxygen species enzyme activity in the brain, and enhanced BNF levels⁷⁵.




Figure 12. Myricetin.

6.4 Quercetin

Known as a pentahydroxy flavone, quercetin is extremely prevalent in pineapple, garlic, ginger, and red wine⁷⁶. Various flavonoid shows potent free radical properties in the treatment of a variety of illnesses and disorders⁷⁶. Additionally, the anxiolytic role was demonstrated in

a few models of animals, where it was discovered that inhibiting MAO substance increased the concentration of 5HT and nor-epinephrine in synaptic clefts. Quercetin has been shown to have antidepressant properties in diabetic rodents, concluded that it might be used in prophylaxis to treat stress in diabetic conditions⁷⁷.




Figure 13. Quercetin

6.5 Rutin

Citrus bioflavonoids such as rutin (tetrahydroxy flavone) are also referred to as sophorin, quercetin, and rutosine. This is comprised of glycoside made up of the flavonoid, myricetin, and the saccharide, with the sugar groups rhamnose and glucose replacing the quercetin's -OH group at position C3. Citrus fruits, vegetables, and plants, including figs, buckwheat, green tea, and others, have all been found to contain^{78,79}. It aids in the body's utilization of vitamin C and collagen production. Rutin was published with various activities such as neuroprotection, antioxidant activity, analgesic properties, and anti-tumor properties^{78,80}. A compound separates out through the methanolic extraction process of *Schinus moll L.* aerial parts, demonstrating CNS suppressive activity in TST. The anti-depressant effects of rutin were supported by increases in the concentration of 5HT and noradrenaline⁸⁰.




Figure 14. Rutin.

7. Conclusion

Anxiety is still a challenging public health issue. Traditional therapies have their limitations, and the proportion of dependent users is rising. To enhance current treatments for stress, this review emphasizes the need for novel medications. To find a more effective and secure substitute, new plant natural components or phytoconstituents are being researched. To increase effectiveness and lessen negative effects, numerous groups of flavonoids may be taken into consideration as supplements to traditional anxiolytic therapy. Even if the findings about containing natural molecules produced from plants are promising, more study is required to understand the correlations, metabolic, distribution, and psychopharmacological processes of these compounds. However, because the bulk of research uses animal models, clinical evaluation is necessary to confirm the therapeutic effects of novel molecules in anxiety-like diseases in humans.

8. Acknowledgment

I want to express my gratitude to the management of NIET (Pharmacy Institute) for providing all kinds of research facilities and encouragement to carry out this review article successfully.

9. References

1. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. *Am J Med Genet C Semin Med Genet.* 2008; 148(2):89-98. <https://doi.org/10.1002/ajmg.c.30172>
2. Kaviani H, Mousavi AS. Psychometric properties of the Persian version of the beck anxiety inventory (BAI). *TUMJ.* 2008; 66(2):136-40.
3. Borkovec TD, Lyonfields JD. Worry: thought suppression of emotional processing. In: Krohne HW, editor. *Attention and avoidance: strategies in coping with aversiveness.* Seattle: Hogrefe and Huber Publishers; 1993. p. 101-8.
4. Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: from animal models to human behavior. *Neuron.* 2005; 48(2):175-87. <https://doi.org/10.1016/j.neuron.2005.09.025>
5. Davis M. Neural systems involved in fear and anxiety measured with a fear-potentiated startle. *Am Psychol.* 2006; 61(8):741-56. <https://doi.org/10.1037/0003-066X.61.8.741>
6. Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuro-anatomy of emotion: A meta-analysis of emotion activation

- studies in PET and fMRI. *Neuroimage*. 2002; 16(2):331-48. <https://doi.org/10.1006/nimg.2002.1087>
7. Quirk GJ, Garcia R, González-Lima F. Prefrontal mechanisms in extinction of conditioned fear. *Biol Psychiatry*. 2006; 60(4):337-43. <https://doi.org/10.1016/j.biopsych.2006.03.010>
 8. Rauch SL, Savage CR, Alpert NM, Fischman AJ, Jenike MA. The functional neuroanatomy of anxiety: A study of three disorders using positron emission tomography and symptom provocation. *Biol Psychiatry*. 1997; 42(6):446-52. [https://doi.org/10.1016/S0006-3223\(97\)00145-5](https://doi.org/10.1016/S0006-3223(97)00145-5)
 9. Malan-Müller S, Hemmings SMJ, Seedat S. Big effects of small RNAs: A review of microRNAs in anxiety. *Mol Neurobiol*. 2013; 47(2):726-39. <https://doi.org/10.1007/s12035-012-8374-6>
 10. Gross C, Hen R. The developmental origins of anxiety. *Nat Rev Neurosci*. 2004; 5(7):545-52. <https://doi.org/10.1038/nrn1429>
 11. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. *Dialogues Clin Neurosci*. 2017; 19(2):93-107. <https://doi.org/10.31887/DCNS.2017.19.2/bbandelow>
 12. Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF, *et al.* Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. *Eur J Clin Pharmacol*. 1997; 53(3-4):163-9. <https://doi.org/10.1007/s002280050357>
 13. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: An update. *Neuropsychiatr Dis Treat*. 2013; 9:883-92. <https://doi.org/10.2147/NDT.S36453>
 14. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. *Toxicol Rev*. 2005; 24(3): 205-14. <https://doi.org/10.2165/00139709-200524030-00013>
 15. Schweizer E, Rickels K, De Martinis N, Case G, García-España F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. *Psychol Med*. 1998; 28(3):713-20. <https://doi.org/10.1017/S0033291798006540>
 16. Berney P, Halperin D, Tango R, Daeniker-Dayer I, Schulz P. A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. *Psychopharmacol Bull*. 2008; 41(3):39-47.
 17. Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, *et al.* Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. *Eur Neuropsychopharmacol*. 2017; 27(5):526-37. <https://doi.org/10.1016/j.euroneuro.2017.02.007>
 18. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. *Hum Psychopharmacol*. 2010; 25(2):95-102. <https://doi.org/10.1002/hup.1094>
 19. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. *J Clin Psychopharmacol*. 2011; 31(4):418-28. <https://doi.org/10.1097/JCP.0b013e318224864d>
 20. Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. *Phytomedicine*. 2010; 17(2):94-9. <https://doi.org/10.1016/j.phymed.2009.10.006>
 21. Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, *et al.* Kava in the treatment of generalized anxiety disorder: A double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol*. 2013; 33(5):643-8. <https://doi.org/10.1097/JCP.0b013e318291be67>
 22. Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: A randomized placebo-controlled pilot study. *Phytother Res*. 2002; 16(7):650-4. <https://doi.org/10.1002/ptr.1027>
 23. Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, *et al.* Comparison of German St. John's wort products according to hyperforin and total hypericin content. *J Am Pharm Assoc (Wash)*. 2001; 41(4):560-6. [https://doi.org/10.1016/S1086-5802\(16\)31280-3](https://doi.org/10.1016/S1086-5802(16)31280-3)
 24. Singh J. Indian gooseberry. Ayur. Times Book Company; 2015.
 25. Singh J. Rauwolfia serpentine-Indian snakeroot. Ayur. Times Book Company. 2016.
 26. Machado DG, Bettio LE, Cunha MP, Capra JC, Dalmarco JB, Pizzolatti MG, *et al.* Antidepressant like effect of the extract of *Rosmarinus officinalis* in mice; involvement of the monoaminergic system. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009; 33(4):642-50. <https://doi.org/10.1016/j.pnpbp.2009.03.004>
 27. Habtemariam S. The therapeutic Potential of Rosemary (*Rosmarinus officinalis*) diterpenes for Alzheimer's disease. *Evid Based Complement Alternat Med*. 2016; 2016:2680409. <https://doi.org/10.1155/2016/2680409>
 28. Calabrese C. Effects of Standardised *Bacopa monnieri* extract on Cognitive performance, Anxiety and Depression in the Elderly. *J Altern Complement Med*. 2008; 14(6):707-13. <https://doi.org/10.1089/acm.2008.0018>
 29. Singh J. Amla Indian gooseberry. Pl. Gallery Press med; 2015
 30. Guerrero PM, *et al.* Antimycotic activity of essential oil of *Lippia citriodora* Kunt (*Aloysia triphylla* Britton). *Riv It EPPPOS*. 1995; 15:23-5.
 31. Valentão P, Fernandes E, Carvalho F, Andrade PB, Seabra RM, de Lourdes Basto M. Studies on the antioxidant activity

- of *Lippia citriodora* infusion: Scavenging effect on superoxide radical, hydroxyl radical and hypochlorous acid. *Biol Pharm Bull.* 2002; 25(10):1324-7. <https://doi.org/10.1248/bpb.25.1324>
32. Qnais E, *et al.* Antinociceptive effect of two flavonoids from *Aloysia triphylla* L. *Jordan J Biol Sci.* 2009; 2(4):167-70.
 33. Abu Zarga MA, Qauasmeh R, Sabri S, Munsoor M, Abdalla S. Chemical constituents of *Artemisia arbore-scens* and the effect of the aqueous extract on rat isolated smooth muscle. *Planta Med.* 1995; 61(3):242-5. <https://doi.org/10.1055/s-2006-958064>
 34. Lu Y, Zhang C, Bucheli P, Wei D. Citrus flavonoids in fruit and traditional Chinese medicinal food ingredients in China. *Plant Foods Hum Nutr.* 2006; 61(2):57-65. <https://doi.org/10.1007/s11130-006-0014-8>
 35. Emim JA, Oliveira AB, Lapa AJ. Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, Duartin and Claussequinone, in rats and mice. *J Pharm Pharmacol.* 1994; 46(2):118-22. <https://doi.org/10.1111/j.2042-7158.1994.tb03753.x>
 36. Agra MdF, Silva KN, Basilio IJLD, Freitas PFd, Barbosa-Filho JM. Survey of medicinal plants used in the region Northeast of Brazil. *Rev Bras Farmacognosia.* 2008; 18(3):472-508. <https://doi.org/10.1590/S0102-695X2008000300023>
 37. Rétiveau AN, Iv EC, Milliken GA. Common and specific effects of fine fragrances on the mood of women. *J Sens Stud.* 2004; 19(5):373-94. <https://doi.org/10.1111/j.1745-459x.2004.102803.x>
 38. Moulehi I, Bourgou S, Ourghemmi I, Tounsi MS. Variety and ripening impact on phenolic composition and antioxidant activity of mandarin (*Citrus reticulate* Blanco) and bitter orange (*Citrus aurantium* L.) seeds extracts. *Ind Crops Prod.* 2012; 39:74-80. <https://doi.org/10.1016/j.indcrop.2012.02.013>
 39. Hwang JH. The effects of the inhalation method using essential oils on blood pressure and stress responses of clients with essential hypertension. *Taehan Kanho Hakhoe Chi.* 2006; 36(7):1123-34. <https://doi.org/10.4040/jkan.2006.36.7.1123>
 40. Gumnick JF, Nemeroff CB. Problems with currently available antidepressants. *J Clin Psychiatry.* 2000; 61(10):5-15.
 41. Hooper, David, Henry Field. Useful plants and drugs of Iran and Iraq. 1937; 69-241.
 42. Abolhassani M. Antibacterial effect of borage (*Echium amoenum*) on *Staphylococcus aureus*. *Braz J Infect Dis.* 2004; 8(5):382-5. <https://doi.org/10.1590/S1413-86702004000500008>
 43. Sayyah M, Boostani H, Pakseresht S, Malaieri A. Efficacy of aqueous extract of *Echium amoenum* in treatment of obsessive-compulsive disorder. *Prog Neuropsychopharmacol Biol Psychiatry.* 2009; 33(8):1513-6. <https://doi.org/10.1016/j.pnpbp.2009.08.021>
 44. Muñoz-Espada AC, Watkins BA. Cyanidin attenuates PGE 2 production and cyclooxygenase-2 expression in LNCaP human prostate cancer cells. *J Nutr Biochem.* 2006; 17(9):589-96. <https://doi.org/10.1016/j.jnutbio.2005.10.007>
 45. Min J, Yu SW, Baek SH, Nair KM, Bae ON, Bhatt A, *et al.* Neuroprotective effect of cyanidin-3-Oglucoside anthocyanin in mice with focal cerebral ischemia. *Neurosci Lett.* 2011; 500(3):157-61. <https://doi.org/10.1016/j.neulet.2011.05.048>
 46. Lis-Balchin M. Aromatherapy science: a guide for health-care professionals. Pharmaceutical press. 2006.
 47. Buchbauer G, Jirovetz L, Jäger W, Dietrich H, Plank C. Aromatherapy: Evidence for sedative effects of the essential oil of lavender after inhalation. *Z Naturforsch C J Biosci.* 1991; 46(11-12):1067-72. <https://doi.org/10.1515/znc-1991-11-1223>
 48. Yamada K, Mimaki Y, Sashida Y. Anticonvulsive effects of inhaling lavender oil vapour. *Biol Pharm Bull.* 1994; 17(2):359-60. <https://doi.org/10.1248/bpb.17.359>
 49. Blumenthal M, *et al.* The complete German Commission E monographs: Therapeutic guide to herbal medicine. Austin: American Botanical Council. 1998.
 50. Emamghoreishi M, Talebianpour MS. Antidepressant effect of *Melissa officinalis* in the forced swimming test. *DARU J Pharm Sci.* 2015; 17(1):42-7.
 51. Taherpour AA, Maroofi H, Rafie Z, Larjani K. Chemical composition analysis of the essential oil of *Melissa officinalis* L. from Kurdistan, Iran by HS/SPME method and calculation of the biophysicochemical coefficients of the components. *Nat Prod Res.* 2012; 26(2):152-60. <https://doi.org/10.1080/14786419.2010.534733>
 52. Shafie-Zadeh F. Lorestan medicinal plants. Lorestan University of Medical Sciences; 2002.
 53. Dibble LE, Hale TF, Marcus RL, Gerber JP, LaStayo PC. High intensity eccentric resistance training decreases bradykinesia and improves quality of life in persons with Parkinson's disease: A preliminary study. *Parkinsonism Relat Disord.* 2009; 15(10):752-7. <https://doi.org/10.1016/j.parkreldis.2009.04.009>
 54. Niranjana R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. *Mol Neurobiol.* 2014; 49(1):28-38. <https://doi.org/10.1007/s12035-013-8483-x>
 55. Sonboli A, Mojarrad M, Nejad Ebrahimi S, Enayat S. Free radical Iran. *Iran J Pharm Res.* 2010; 9(3):293-6.
 56. Arctander S. Perfume and flavor materials of natural origin. Perfume Flavor Mater Nat Orig. 1960.
 57. Ebrahimzadeh MA, Nabavi SM, Nabavi SF, Bahramian F, Bekhradnia AR. Antioxidant and free radical scavenging activity of *H. officinalis* L. var. angustifolius, *V. odorata*. *Pak J Pharm Sci.* 2010; 23(1):29-34.
 58. Vishal A, *et al.* Diuretic, laxative and toxicity Studies of *Viola odorata* aerial parts. *Pharmacol.* 2009; 1:739-48.

59. *Cimicifuga racemosa* (L.) Nutt. American herbal pharmacopoeia botanical pharmacognosy. *Actea racemosa* L. syn. In: Upton R, editor. American herbal pharmacopoeia botanical pharmacognosy. CRC Press. 2011; 217-22.
60. Mohammad-Alizadeh-Charandabi S, Shahnazi M, Nahae J, Bayatipayan S. Efficacy of black cohosh (*Cimicifuga racemosa* L.) in treating early symptoms of menopause: A randomized clinical trial. *Chin Med*. 2013; 8(1):20. <https://doi.org/10.1186/1749-8546-8-20>
61. Nikolić D, Li J, Van Breemen RB. Metabolism of Nmethylserotonin, a serotonergic constituent of black cohosh. *Biomed Chromatogr*. 2014; 28(12):1647-51. <https://doi.org/10.1002/bmc.3197>
62. Amsterdam JD, Yao Y, Mao JJ, Soeller I, Rockwell K, Shults J. Randomized, double-blind, placebo-controlled trial of *Cimicifuga racemosa* (black cohosh) in women with anxiety disorder due to menopause. *J Clin Psychopharmacol*. 2009; 29(5):478-83. <https://doi.org/10.1097/JCP.0b013e3181b2abf2>
63. Sarris J, Kean J, Schweitzer I, Lake JH. Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder (ADHD): A systematic review of the evidence. *Complement Ther Med*. 2011; 19(4):216-27. <https://doi.org/10.1016/j.ctim.2011.06.007>
64. Schirrmacher K, Busselberg D, Langosch JM, Walden J, Winter U, Bingmann D. Effects of (-)-kavain on voltage activated inward currents of dorsal rhizome ganglion cells from neonatal rats. *Eur. Neuropsychopharmacol*. 1999; 9:171-176. [https://doi.org/10.1016/S0924-977X\(98\)00008-X](https://doi.org/10.1016/S0924-977X(98)00008-X)
65. Wu D, Yu L, Nair MG, DeWitt DL, Ramsewak RS. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from *Piper methysticum* (kava-kava) roots. *Phytomedicine*. 2002; 9(1):41-7. <https://doi.org/10.1078/0944-7113-00068>
66. Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, *et al*. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol*. 2013; 33(5):643-8. <https://doi.org/10.1097/JCP.0b013e318291be67>
67. Ketola RA, Viinamäki J, Rasanen I, Pelander A, Goebeler S. Fatal kavalactones intoxication by suicidal intravenous injection. *Forensic Sci Int*. 2015; 249:e7-11. <https://doi.org/10.1016/j.forsciint.2015.01.032>
68. Nakazawa T, Yasuda T, Ueda J, Ohsawa K. Antidepressant-like effects of apigenin and 2,4,5-trimethoxycinnamic acid from *Perilla frutescens* in the forced swimming test. *Biol Pharm Bull*. 2003; 26(4):474-80. <https://doi.org/10.1248/bpb.26.474>
69. Li R, Wang X, Qin T, Qu R, Ma S. Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1 β production and NLRP3 inflammasome activation in the rat brain. *Behav Brain Res*. 2016; 296:318-25. <https://doi.org/10.1016/j.bbr.2015.09.031>
70. Li RP, Zhao D, Qu R, Fu Q, Ma SP. The effects of apigenin on lipopolysaccharide-induced depressive-like behavior in mice. *Neurosci Lett*. 2015; 594:17-22. <https://doi.org/10.1016/j.neulet.2015.03.040>
71. Liu C, Wu J, Gu J, Xiong Z, Wang F, Wang J, *et al*. Baicalein improves cognitive deficits induced by chronic cerebral hypoperfusion in rats. *Pharmacol Biochem Behav*. 2007; 86(3):423-30. <https://doi.org/10.1016/j.pbb.2006.11.005>
72. Lee B, Sur B, Park J, Kim SH, Kwon S, Yeom M, *et al*. Chronic administration of baicalein decreases depression-like behavior induced by repeated restraint stress in rats. *Korean J Physiol Pharmacol*. 2013; 17(5):393-403. <https://doi.org/10.4196/kjpp.2013.17.5.393>
73. Li YC, Shen JD, Li J, Wang R, Jiao S, Yi LT. Chronic treatment with baicalin prevents the chronic mild stress-induced depressive-like behavior: involving the inhibition of cyclooxygenase-2 in rat brain. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013; 40:138-43. <https://doi.org/10.1016/j.pnpbp.2012.09.007>
74. Taheri Y, Suleria HAR, Martins N, Sytar O, Beyatli A, Yeskaliyeva B, *et al*. Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications. *BMC Complement Med Ther*. 2020; 20(1):241. <https://doi.org/10.1186/s12906-020-03033-z>
75. Ma Z, Wang G, Cui L, Wang Q. Myricetin attenuates depressant-like behavior in mice subjected to repeated restraint stress. *Int J Mol Sci*. 2015; 16(12):28377-85. <https://doi.org/10.3390/ijms161226102>
76. Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, *et al*. Quercetin, inflammation and immunity. *Nutrients*. 2016; 8(3):167. <https://doi.org/10.3390/nu8030167>
77. Demir EA, Gergerlioglu HS, Oz M. Antidepressant like effects of quercetin in diabetic rats are independent of hypothalamic-pituitary-adrenal axis. *Acta Neuropsychiatry*. 2016; 28(1):23-30. <https://doi.org/10.1017/neu.2015.45>
78. Ganeshpurkar A, Saluja AK. The pharmacological potential of Rutin. *Saudi Pharm J*. 2017; 25(2):149-64. <https://doi.org/10.1016/j.jsps.2016.04.025>
79. Al-Dhabi NA, Arasu MV, Park CH, Park SU. An up-to-date review of rutin and its biological and pharmacological activities. *Excli J*. 2015; 14:59-63. doi: 10.17179/excli2014-663.
80. Gullón B, Lú-Chau TA, Moreira MT, Lema JM, Eibes G. Rutin: A review on extraction, identification and purification methods, biological activities, and approaches to enhance its bioavailability. *Trends Food Sci Technol*. 2017; 67:220-35. <https://doi.org/10.1016/j.tifs.2017.07.008>